Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590065 | 0.86 | AKR1C3 (0.60) | AKR1C3ESR2KMT2AMEN1HDAC6 | |
| SCHEMBL20046992 | 0.83 | HDAC6 (0.69) | AKR1C3ESR2KMT2AMEN1HDAC6 | |
| SCHEMBL5915341 | 0.81 | KMT2A (0.77) | AKR1C3ESR2AKR1C1KMT2AMEN1 | |
| SCHEMBL5632531 | 0.81 | AKR1C3 (0.60) | AKR1C3ESR2AKR1C1PDE4BKMT2A | |
| SCHEMBL723811 | 0.81 | MEN1 (0.68) | AKR1C3ESR2KMT2AMEN1HDAC6 | |
| SCHEMBL38665856 | 0.81 | AKR1C3 (0.55) | AKR1C3ESR2AKR1C1KMT2AMEN1 | |
| SCHEMBL31670441 | 0.81 | AKR1C3 (0.73) | AKR1C3ESR2AKR1C1KMT2AMEN1 | |
| SCHEMBL20047121 | 0.80 | KMT2A (0.54) | AKR1C3ESR2AKR1C1PDE4BKMT2A | |
| SCHEMBL22504152 | 0.78 | AKR1C3 (0.55) | AKR1C3ESR2KMT2AMEN1HDAC6 | |
| SCHEMBL5632587 | 0.78 | AKR1C3 (0.77) | AKR1C3ESR2AKR1C1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | NR1H2, NR1H3, PPARD | AKR1C3 1019/4885ESR2 11/4885AKR1C1 919/4885 |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | AKR1C3 1019/4885ESR2 11/4885AKR1C1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.